UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Annals of oncology, 2019-06, Vol.30 (6), p.970-976

2019

Volltextzugriff (PDF)

BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)

Annals of oncology, 2018-10, Vol.29, p.viii331-viii331

2018

Volltextzugriff (PDF)

Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial

Annals of oncology, 2018-10, Vol.29, p.viii304-viii304

2018

Volltextzugriff (PDF)

Predicting Outcome to Chemotherapy in Patients With Germ Cell Tumors: The Value of the Rate of Decline of Human Chorionic Gonadotrophin and Alpha-Fetoprotein During Therapy

Journal of clinical oncology, 2001-05, Vol.19 (9), p.2534-2541

2001

Volltextzugriff (PDF)

Résultats actualisés de l’essai de phase 3 checkmate 274 évaluant nivolumab adjuvant (NIVO) versus placebo (PBO) chez les patients atteints de carcinome urothélial infiltrant le muscle (CUIM) à haut risque après résection complète

Progrès en urologie. Formation médicale continue, 2023-11, Vol.33 (3), p.S67

2023

Volltextzugriff (PDF)

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Annals of oncology, 2018-10, Vol.29, p.viii320-viii321

2018

Volltextzugriff (PDF)

Résultats actualisés de survie sans maladie (DFS) de l’essai de phase 3 CheckMate 274, évaluant le nivolumab en adjuvant chez les patients atteints d’un carcinome urothélial infiltrant le muscle à haut risque de récidive (CUIM-HR) après exérèse complète

Progrès en urologie. Formation médicale continue, 2022-11, Vol.32 (3), p.S97-S98

2022

Volltextzugriff (PDF)

Commentary on “DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.”

Urologic oncology, 2018-07, Vol.36 (7), p.345-346

2018

Volltextzugriff (PDF)

Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study

European journal of cancer (1990), 2017-02, Vol.72, p.S2-S2

2017

Volltextzugriff (PDF)

Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome

Journal of clinical oncology, 1998-04, Vol.16 (4), p.1298-1301

1998

Volltextzugriff (PDF)

Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients

Journal of clinical oncology, 2000-03, Vol.18 (6), p.1173-1180

2000

Volltextzugriff (PDF)

Association Between Geographic Access and Receipt of Radiation Therapy

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E367-E367

2015

Volltextzugriff (PDF)

Deleterious Alterations in DNA Damage Response Genes Are Associated With Improved Outcome in Muscle-Invasive Bladder Cancer Patients Treated With Radiation-Based Bladder Preservation

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E248-E248

2015

Volltextzugriff (PDF)

2650 Assessment of genomic alterations in bladder adenocarcinoma and urachal adenocarcinoma

European journal of cancer (1990), 2015-09, Vol.51, p.S530-S530

2015

Volltextzugriff (PDF)

High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors

Journal of clinical oncology, 1997-07, Vol.15 (7), p.2546-2552

1997

Volltextzugriff (PDF)

High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity

Journal of clinical oncology, 1996-04, Vol.14 (4), p.1098-1105

1996

Volltextzugriff (PDF)

Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival

Journal of clinical oncology, 1997-07, Vol.15 (7), p.2559-2563

1997

Volltextzugriff (PDF)

Spécificités moléculaires des tumeurs de la voie excrétrice urinaire supérieure

Progrès en urologie (Paris), 2018-11, Vol.28 (13), p.680-681

2018

Volltextzugriff (PDF)

Classification phylogénétique des récidives vésicales après tumeur de la voie excrétrice urinaire supérieure

Progrès en urologie (Paris), 2018-11, Vol.28 (13), p.681-681

2018

Volltextzugriff (PDF)

Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumors—An Update

Urology (Ridgewood, N.J.), 2011-03, Vol.77 (3), p.655-659

2011

Volltextzugriff (PDF)

Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse

Journal of clinical oncology, 2001-04, Vol.19 (7), p.2020-2025

2001

Volltextzugriff (PDF)

Recommendations for a Global Core Curriculum in Medical Oncology

Annals of oncology, 2004-11, Vol.15 (11), p.1603-1612

2004

Volltextzugriff (PDF)

POST-CHEMOTHERAPY SURGERY IN PATIENTS WITH UNRESECTABLE OR REGIONALLY METASTATIC BLADDER CANCER

The Journal of urology, 2001-03, Vol.165 (3), p.811-814

2001

Volltextzugriff (PDF)

Surgery for a Post-Chemotherapy Residual Mass in Seminoma

The Journal of urology, 1997-03, Vol.157 (3), p.860-862

1997

Volltextzugriff (PDF)

Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer

Journal of clinical oncology, 2001-09, Vol.19 (18), p.17s-20s

BAJORIN, Dean F

2001

Volltextzugriff (PDF)

1 – 25 von 309

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(288)
Mit Volltextzugriff
(244)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(127)
Science & Technology
(123)
Life Sciences & Biomedicine
(117)
Oncology
(83)
Male
(68)
Biological And Medical Sciences
(67)
Medical Sciences
(67)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(56)
Adult
(45)
Tumors
(40)
Prognosis
(34)
Testicular Neoplasms - Drug Therapy
(33)
Pharmacology. Drug Treatments
(32)
Chemotherapy
(31)
Middle Aged
(30)
Urology & Nephrology
(30)
Antineoplastic Agents
(28)
Germinoma - Drug Therapy
(28)
Urinary Bladder Neoplasms - Drug Therapy
(27)
Cisplatin - Administration & Dosage
(26)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)

Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial

Predicting Outcome to Chemotherapy in Patients With Germ Cell Tumors: The Value of the Rate of Decline of Human Chorionic Gonadotrophin and Alpha-Fetoprotein During Therapy

Résultats actualisés de l’essai de phase 3 checkmate 274 évaluant nivolumab adjuvant (NIVO) versus placebo (PBO) chez les patients atteints de carcinome urothélial infiltrant le muscle (CUIM) à haut risque après résection complète

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Résultats actualisés de survie sans maladie (DFS) de l’essai de phase 3 CheckMate 274, évaluant le nivolumab en adjuvant chez les patients atteints d’un carcinome urothélial infiltrant le muscle à haut risque de récidive (CUIM-HR) après exérèse complète

Commentary on “DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.”

Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study

Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome

Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients

Association Between Geographic Access and Receipt of Radiation Therapy

Deleterious Alterations in DNA Damage Response Genes Are Associated With Improved Outcome in Muscle-Invasive Bladder Cancer Patients Treated With Radiation-Based Bladder Preservation

2650 Assessment of genomic alterations in bladder adenocarcinoma and urachal adenocarcinoma

High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors

High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity

Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival

Spécificités moléculaires des tumeurs de la voie excrétrice urinaire supérieure

Classification phylogénétique des récidives vésicales après tumeur de la voie excrétrice urinaire supérieure

Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumors—An Update

Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse

Recommendations for a Global Core Curriculum in Medical Oncology

POST-CHEMOTHERAPY SURGERY IN PATIENTS WITH UNRESECTABLE OR REGIONALLY METASTATIC BLADDER CANCER

Surgery for a Post-Chemotherapy Residual Mass in Seminoma

Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer

Aktive Filter

Suchergebnisse filtern